Your Health, We Care
Olaparib, as a polyadenosine diphosphate ribose polymerase (PARP) inhibitor, has made significant progress in the field of cancer treatment in recent years.
The United States Food and Drug Administration (FDA) has approved olaparib for the treatment of HER2-negative metastatic breast cancer harboring BRCA gene mutations, bringing new hope to BRCA mutant breast cancer patients.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
